Catalyst Pharmaceuticals (CPRX)

Add to Watchlists
Create an Alert
2.51 -0.03  -1.18% NASDAQ Apr 20, 20:00 Delayed 2m USD

Catalyst Pharmaceuticals Research and Development Expense (Quarterly):

3.405M for Dec. 31, 2017
View 4,000+ financial data types
View Full Chart

Catalyst Pharmaceuticals Research and Development Expense (Quarterly) Chart

Export Data
Save Image
Print Image

Catalyst Pharmaceuticals Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 2004. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
Dec. 31, 2017 3.405M
Sept. 30, 2017 2.705M
June 30, 2017 2.452M
March 31, 2017 2.814M
Dec. 31, 2016 2.821M
Sept. 30, 2016 2.494M
June 30, 2016 2.509M
March 31, 2016 3.546M
Dec. 31, 2015 3.832M
Sept. 30, 2015 3.043M
June 30, 2015 2.578M
March 31, 2015 2.350M
Dec. 31, 2014 2.384M
Sept. 30, 2014 2.886M
June 30, 2014 2.099M
March 31, 2014 2.749M
Dec. 31, 2013 2.068M
Sept. 30, 2013 2.804M
June 30, 2013 2.132M
March 31, 2013 1.092M
Dec. 31, 2012 0.7447M
Sept. 30, 2012 0.6548M
June 30, 2012 0.5327M
March 31, 2012 0.7273M
Dec. 31, 2011 0.9602M
Sept. 30, 2011 0.6141M
June 30, 2011 0.9056M
March 31, 2011 0.904M
Dec. 31, 2010 0.5692M
Sept. 30, 2010 0.5001M
June 30, 2010 0.7979M
March 31, 2010 0.4396M
Dec. 31, 2009 0.5476M
Sept. 30, 2009 0.851M
June 30, 2009 1.238M
March 31, 2009 2.461M
Dec. 31, 2008 3.272M
Sept. 30, 2008 2.452M
June 30, 2008 1.902M
March 31, 2008 1.084M
Dec. 31, 2007 0.722M
Sept. 30, 2007 0.5033M
June 30, 2007 1.003M
March 31, 2007 0.7625M
Dec. 31, 2006 0.3209M
Sept. 30, 2006 0.2355M
June 30, 2006 0.2701M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More


CPRX Research and Development Expense (Quarterly) Benchmarks

RXi Pharmaceuticals 1.204M
MYnd Analytics 0.3507M
SELLAS Life Sciences Group 0.951M

CPRX Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 2.068M Dec 2013
Maximum 3.832M Dec 2015
Average 2.719M

CPRX Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("CPRX", "r_and_d_expense")
  • Last 5 data points: =YCS("CPRX", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.




Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.